Current recommendations for the prevention and treatment of hereditary breast cancer;Aktuelle empfehlungen zur prävention und therapie des familiären mammakarzinoms

Geburtshilfe und Frauenheilkunde

Volumn 70, Issue 8, 2010, Pages 634-639

  Kast, K ^a   Distler, W ^a   Schmutzler, R ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

BRCA1; BRCA2; prevention program; prophylactic operation; therapy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER PREVENTION; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; CLINICAL ASSESSMENT; GENE EXPRESSION; GENE MUTATION; HEREDITARY BREAST CANCER; HETEROZYGOTE; HUMAN; METASTASIS; OVARY CANCER; PROGNOSIS; QUALITY OF LIFE; RADIODIAGNOSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SALPINGOOOPHORECTOMY; SYSTEMIC THERAPY;

EID: 77955855986     PISSN: 00165751     EISSN: 14388804     Source Type: Journal    
DOI: 10.1055/s-0030-1250167     Document Type: Review

References (33)

1. Atchley D P., Albarracin C T., Lopez A et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008 26 4282-4288
2. Budroni M, Cesaraccio R, Coviello V et al. Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer 2009 9 62
3. Rennert G, Bisland-Naggan S, Barnett-Grinnes O et al. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007 357 115-123 (Pubitemid 47057729)
4. Brekelmans C T. M., Seynaeve C, Menke-Pluymers M et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncology 2006 17 391-400
5. Robson M E., Chappuis P O., Satagopan J et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004 6 8-17
6. Hagen A I., Tretli S, Maele L et al. Survival in Norwegian BRCA1 mutation carriers with breast cancer. Hered Cancer Clin Practice 2009 7 7
7. Byrski T, Gornwald J, Huzarski T et al, The Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008 108 289-296
8. Husain A, He G, Venkatraman E S. et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 1998 58 1120-1123
9. Tan D S. P., Rothermundt C, Thomas K et al. BRCAness syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008 26 5530-5536
10. Cass I, Baldwin R L., Varkey T et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003 97 2187-2195
11. Bryant H, Schultz N, Thomas H et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005 434 913-916
12. Farmer H, McCabe N, Lord C J. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 434 917-921
13. Moynahan M E., Pierce A J., Jasin M. BRCA2 is required for homology directed repair of chromosomal breaks. Mol Cell 2001 7 263-272
14. Meric-Bernstam F. Heterogenic loss of BRCA in breast cancer: the two-hit hypothesis takes a hit. An Surg Oncol 2007 14 2428-2429
15. Risch H A., McLaughlin J R., Cole D E. C. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001 68 700-710
16. Antoniou A, Pharoah P D., Narod S et al. Average risk of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003 72 1117-1130
17. King M C., Mraks J H., Mandell J B., for the New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003 302 643-646
18. Meijers-Heijboer H, van den Ouweland A, Klijn J et al., CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002 31 55-59
19. Teraoka S N., Malone K E., Doody D R. et al. Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and ovarian cancer. Cancer 2001 93 479-487
20. Antoniou A C., Spurdle A B., Sinilnikova O M. et al. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008 82 937-948
21. Robson M E., Svahn T, McCormick B et al. Appropriateness of breast-conserving treatment of brest carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 2005 103 44-51
22. Metcalfe K A., Lynch H T., Ghadirian P et al. Contralateral breast cancer in BRCA1 and BRCA2 carriers. J Clin Oncol 2004 22 2328-2335
23. Pierce L J., Levin A M., Rebbeck T R. et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006 24 2437-2443
24. Hartmann L C., Sellers T A., Schaid D J. et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001 93 1633-1637
25. Rebbeck T R., Friebel T, Lynch H T. et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncology 2004 22 1055-1062 (Pubitemid 41095038)
26. Temple W J., Lindsay R L., Magi E et al. Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am J Surg 1991 161 413-415
27. Spear S L., Schwarz K A., Venturi M L. et al. Prophylactic mastectomy and reconstruction: clinical outcomes and patient satisfaction. Breast 2008 122 1-9
28. Metcalfe K A., Semple J L., Narod S A. Time to reconsider subcutaneous mastectomy for breast cancer prevention? Lancet Oncol 2005 6 431-434
29. Carcangiu M L., Peissel B, Pasini B et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol 2006 30 1222-1230
30. Hermsen B B. J., van Diest P J., Berkhof J et al. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer 2006 119 1412-1418
31. Metcalfe K A., Finch A, Poll A et al. Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 2009 100 421-425
32. Kauff N D., Mitra N, Robson M E. et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005 97 1382-1384
33. Tilanus-Linthorst M M. A., Alves C, Seynaeve C et al. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer. Br J Surg 2006 93 961-968